Picture: CT pictures of a affected person who has developed pneumonia as a complication of COVID-19 and evaluation outcomes (Picture courtesy of Fujifilm Company)
Fujifilm Company (Tokyo, Japan) will start a analysis examine to develop Synthetic Intelligence (AI)-based expertise to help within the prognosis and remedy evaluation of sufferers with COVID-19-induced pneumonia.
Fujifilm has been engaged on growing AI expertise that can be utilized for helping medical diagnostic imaging, facilitating workflow on the medical frontline and delivering upkeep companies for medical gear. Fujifilm will apply the CT quantification expertise for interstitial pneumonia to develop the expertise that helps consider the progress of sufferers with COVID-19-induced pneumonia and decide the effectiveness of therapies.
Fujifilm’s CT quantification expertise for interstitial pneumonia is powered by an AI-based software program that examines CT pictures to determine bronchi, blood vessels and regular lungs in lung subject in addition to seven varieties of lesions reminiscent of reticular opacities, ground-glass opacities and honeycomb lungs, and routinely carries out categorization and measurement to quantify lesions of interstitial pneumonia. It additionally divides the lung subject into 12 zones and reveals the amount and ratio of lesions for every of the zones in order that clinicians can study the distribution and development of lesions inside the lung subject in particulars. As well as, the expertise is anticipated to contribute to accelerating the event and analysis of drug candidates for treating pneumonia induced by COVID-19.